As drug-induced NRF2 activation in the tumour microenvironment will have a broad anti-oxidative effect across all immune cell types, we propose that small molecule modulation of NRF2 activity has the potential to function as a new complementary therapeutic strategy to enhance the anti-cancer immune response and synergize with existing immune checkpoint inhibitor treatment protocols. The gene discussed is NFE2L2; the disease is cancer.